Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Rosiglitazone on Regression of Atherosclerosis: A Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Study

NCT00166803 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT00166803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00166803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Rosiglitazone on Regression of Atherosclerosis: A Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Study
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Suspended
Start date
June 30, 2005
Completion date
Not reported
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, atherosclerosis